Stay updated on Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe site footer revision number was updated from v3.5.2 to v3.5.3, indicating a website/version refresh without changing the trial details.SummaryDifference0.1%

- Check26 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check54 days agoChange DetectedRevision label updated to v3.5.0, replacing v3.4.3. This appears to be an internal version update with no changes to the study content.SummaryDifference0.1%

- Check61 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check90 days agoChange DetectedThe revision label was updated from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check97 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1. No changes to study content or eligibility criteria are indicated.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page.